Table 2.
Results from multivariable logistic regression analysis for the relationship between trial characteristics and high-enrollment of BIPOC groups
| Trial factors | OR (95%CI) | P |
|---|---|---|
| Year of publication | ||
| 2000–2009 | Ref | - |
| 2010–2020 | 1.75 (0.95, 3.22) | 0.074 |
| Sample size ≥ 716a | 0.98 (0.64, 1.51) | 0.944 |
| Diabetes type | ||
| Other | Ref | - |
| Type 2 diabetes | 1.44 (1.04, 1.99) | 0.027 |
| Enrollment location | ||
| Other | Ref | - |
| Ambulatory | 0.55 (0.27, 1.12) | 0.097 |
| Random type | ||
| Cluster | Ref | - |
| Individual | 1.00 (0.15, 6.69) | 0.998 |
| Trial primary objective | ||
| Complication | Ref | - |
| Glucose control | 1.48 (0.75, 2.89) | 0.256 |
| Management or mixed | 0.86 (0.48, 1.57) | 0.628 |
| Intervention | ||
| Type of intervention | ||
| Others | Ref | - |
| Medication | 0.82 (0.38, 1.77) | 0.617 |
| Frequency of intervention | ||
| Others | Ref | - |
| Weekly/daily | 0.48 (0.26, 0.91) | 0.024 |
| Duration of intervention > 6.5 montha | 0.59 (0.37, 0.95) | 0.030 |
| Follow-up | ||
| Type of follow-up | ||
| Others | Ref | - |
| Face-to-face | 0.71 (0.41, 1.23) | 0.221 |
| Frequency of follow-up | ||
| Other | Ref | - |
| Weekly/monthly | 1.28 (0.62, 2.66) | 0.503 |
| Duration of follow-up > 12 monthsa | 1.45 (0.88, 2.38) | 0.147 |
| Funding source | ||
| Non-industry | Ref | - |
| Industry | 0.86 (0.49, 1.53) | 0.614 |
aThe cut-off point was determined by using the median value
Ref reference category/level